By Jon Chesto When demand for office space cratered during the COVID-19 pandemic, many developersdoubled down on building lab space instead. Lately, it sure seems like they went overboard. With newly builtlife sciences buildings hitting the market at a much faster rate than they can be filled, the availability of lab space in Greater Boston […]
By Hannah Green Venture capital funding to life sciences companies appears to be rebounding nationally after a few down years, according to new data from Pitchbook and the National Venture Capital Association. But that’s not the case among Massachusetts life sciences companies. Nationally, life sciences companies brought in $19.3 billion in the first six months of 2024. Last […]
By Hannah Green Charles River Labs has a new facility coming to Somerville next month. The Wilmington-based contract research company is opening a Charles River Accelerator and Development Lab (CRADL) site on Chestnut Street in Somerville at the end of July. Charles River Laboratories International Inc. (NYSE: CRL) provides products and services to pharma and biotech companies to […]
By: Emily Fu North River Leerink (NRL) has announced that 100 Chestnut, a purpose-built 200,000 square feet life Science building in Somerville, MA, is 90% leased. Ultragenyx, relocating from Kendall Square, has leased 42,500 square feet to consolidate their east coast R&D. CRADL has leased 16,000 square feet to open a contract vivarium and in […]
By Hannah Green A Framingham-based biotech is relocating its headquarters to a new space closer to the center of Massachusetts’ biotech industry. BPGbio announced on Wednesday it was moving into 70,000 square feet of lab and office space at 300 Third Avenue in Waltham. The biotech company plans to move into two full floors of the […]
By Richard Berger There are early signs of recovery within the life sciences environment following a recent investment slowdown as venture capital is re-emerging, tenants are coming off the sidelines and average deal sizes are hitting all-time highs, according to a recent report from Cushman & Wakefield. Its research manager, Sandy Romero, said venture capital […]
By Rowan Walrath In a first for the Nobel Prize-winning gene-editing technology, a CRISPR-based drug has been approved in the U.S. The Food and Drug Administration gave the green light Friday to exa-cel, a drug made by two Boston-based companies, Vertex Pharmaceuticals Inc. (Nasdaq: VRTX) and CRISPR Therapeutics Inc. (Nasdaq: CRSP). It will be marketed under […]
By Rowan Walrath Somerville’s bluebird bio Inc. has won its third U.S. drug approval since splitting into two companies. On Friday, the Food and Drug Administration approved lovo-cel, a gene therapy for sickle-cell disease. The drug will be marketed under the name Lyfgenia. The FDA announced Lyfgenia’s approval at the same time it said it had approved […]
By Rowan Walrath A consortium of leaders in the private and public sectors are making a push for Massachusetts to play host to a hub of a new, biomedical research-focused federal agency. ARPA-H, short for the Advanced Research Projects Agency for Health, is tasked with kickstarting biomedical innovation. While its home base will be in the […]
By Rowan Walrath Massachusetts’ life sciences industry grew by more than 7,000 jobs last year, outpacing competitor states even as the so-called “Covid boom” began to wane. That’s according to the latest “Industry Snapshot” report put out by the Massachusetts Biotechnology Council, the trade group better known as MassBio, which examines trends in workforce, real estate, […]
